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Hyperinsulinemia is associated with obesity and
pancreatic islet hyperplasia, but whether insulin
causes these phenomena or is a compensatory
response has remained unsettled for decades. We
examined the role of insulin hypersecretion in diet-
induced obesity by varying the pancreas-specific
Ins1 gene dosage in mice lacking Ins2 gene expres-
sion in the pancreas, thymus, and brain. Age-depen-
dent increases in fasting insulin and b cell mass
were absent in Ins1+/:Ins2/ mice fed a high-fat
diet when compared to Ins1+/+:Ins2/ littermate
controls. Remarkably, Ins1+/:Ins2/ mice were
completely protected from diet-induced obesity.
Genetic prevention of chronic hyperinsulinemia in
this model reprogrammed white adipose tissue to
express uncoupling protein 1 and increase energy
expenditure. Normalization of adipocyte size and
activation of energy expenditure genes in white
adipose tissue was associated with reduced inflam-
mation, reduced fatty acid spillover, and reduced
hepatic steatosis. Thus, we provide genetic evidence
that pathological circulating hyperinsulinemia drives
diet-induced obesity and its complications.
INTRODUCTION
Obesity is a worldwide epidemic with increasing prevalence
and is a major independent risk factor for heart disease, hyper-
tension, stroke, diabetes, cancer, and many other diseases
(Despre´s and Lemieux, 2006; Olshansky et al., 2005). Themolec-
ular causes of obesity remain largely unexplained, despite the
identification of common gene variants that contribute modest
risk (Frayling et al., 2007). Obesity research has benefited from
animal models in which genetic and environmental factors can
be manipulated in ways that are impossible with humans. For
example, invertebrates with reduced insulin or insulin signaling
have leaner, smaller bodies, along with increased life span
(Broughton et al., 2008; Li et al., 2003). Studies in mammals point
to cell type-specific roles for the insulin receptor in diet-inducedCell Mobesity. Fat-specific insulin receptor knockout mice are pro-
tected from diet-induced obesity and have extended longevity
(Blu¨her et al., 2002; Katic et al., 2007), whereas elimination of
insulin receptors from some, but not all, brain regions increases
food intake and obesity (Bru¨ning et al., 2000; Ko¨nner and Bru¨n-
ing, 2012). The interpretation of studies involving insulin receptor
ablation is confounded by compensation between tissues and
disruption of insulin-like growth factor signaling involving hybrid
receptors (Blu¨her et al., 2002; Kitamura et al., 2003). Moreover,
knockout of the insulin receptor, by definition, induces tissue-
specific insulin resistance, which alone may promote hypergly-
cemia and insulin hypersecretion (Bru¨ning et al., 1998; Kitamura
et al., 2003). Previous studies have been unable to determine the
role of hyperinsulinemia on obesity in the absence of insulin
resistance and glucose intolerance.
It is a widely held view that hyperinsulinemia simply represents
a compensation for systemic insulin resistance. Nevertheless,
the cause-and-effect relationships between hyperinsulinemia,
insulin resistance, obesity, and type 2 diabetes remain unre-
solved. Reports of elevated insulin secretion at birth, and of
insulin hypersecretion preceding obesity or insulin resistance,
are inconsistent with hyperinsulinemia being merely an adaptive
response (Genuth et al., 1971; Gray et al., 2010; Ishikawa et al.,
1998; Kitamura et al., 2003; Koopmans et al., 1997; Le Stunff and
Bougne`res, 1994; Lustig, 2006; Odeleye et al., 1997; Shanik
et al., 2008; Zimmet et al., 1991). Furthermore, blocking hyperin-
sulinemia with drugs including diazoxide or octreotide can cause
weight loss in humans (Alemzadeh et al., 1998; Lustig et al.,
2006), although interpretation of these studies is complicated
by direct effects of these treatments on multiple tissues, in-
cluding white fat (Shi et al., 1999) and brain (Pocai et al., 2005).
Thus, although circumstantial evidence points to a role for hyper-
insulinemia in the development of obesity, to date, there has
been no direct evidence that circulating insulin itself drives
obesity in mammals. To directly test this hypothesis, one would
ideally genetically lower the amount of pancreatic insulin avail-
able without crossing the threshold that would result in diabetes.
Members of the insulin gene family are evolutionarily con-
served products of neurosecretory cells (Broughton et al.,
2008; Li et al., 2003). In mammals, insulin is recognized for its
critical metabolic roles, whereas the insulin-like growth factors
are most often associated with tissue growth. Evidence from
our group and others points to important growth factor roles of
insulin (Blu¨her et al., 2002; Johnson and Alejandro, 2008; Okadaetabolism 16, 723–737, December 5, 2012 ª2012 Elsevier Inc. 723
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Insulin Gene Dosage Controls Mammalian Obesityet al., 2007). Mice and rats have two insulin genes, producing
hormones with similar peptide sequences. Deletion of both
rodent insulin genes causes death from neonatal diabetes (Duvil-
lie´ et al., 1997). It has been reported that ablation of either Ins1 or
Ins2 from the mouse genome does not result in significant
changes in glucose homeostasis in young mice fed a normal
diet, implying compensation or redundancy with regards to
metabolism (Duvillie´ et al., 1997; Leroux et al., 2001). However,
there is evidence that the two rodent insulin genes have specific
tissue distribution patterns suggesting some nonoverlapping
functions (Kojima et al., 2004; Moore et al., 2001; Pugliese
et al., 1997). Most studies have shown that Ins1 is restricted to
pancreatic b cells, where it contributes to approximately one-
third of the expressed and secreted insulin (Hay and Docherty,
2006). Ins2 is the ancestral gene, with gene structure, parental
imprinting, and a broad tissue distribution similar to human INS
(Deltour et al., 1993; Hay and Docherty, 2006).
In the present study, we took advantage of the pancreas-
specific expression of the murine Ins1 gene to demonstrate
that diet-induced pancreatic insulin hypersecretion promotes
obesity and its associated complications in this model. Mice
made genetically incapable of high-fat diet-induced fasting hy-
perinsulinemia had increased levels of Ucp1 in white adipose
tissue and increased energy expenditure. These results have
profound implications for our understanding of the role of insulin
in obesity and reveal unappreciated in vivo connections between
fasting hyperinsulinemia and adipocyte reprogramming. As the
human INS gene is subject to genetic variation (Le Stunff et al.,
2001), our results suggest a mechanism for establishing obesity
susceptibility to dietary stress.
RESULTS
Ins2, but Not Ins1, Is Expressed in the Central Nervous
System
While it is clear that pancreatic b cells are the only significant
source of circulating hormonal insulin, it is known that some cells
outside the pancreas express modest amounts of Ins2/INS. For
example, Ins2 production in the thymus is widely accepted to
play a role in immune tolerance (Fan et al., 2010; Pugliese et al.,
1997). Over 80 reports have suggested that insulin can be
produced in the brain (de la Monte and Wands, 2008; DeltourFigure 1. Central Nervous System Expression of Ins2, but Not Ins1
(A) Analysis of Ins2 and Ins1 mRNA expression (relative to the control gene) in th
C57Bl6/J mice.
(B) No significant compensatory upregulation of either insulin gene in Ins1/:Ins2
the qRT-PCR. Further validation of the specificity of mouse Ins1 and Ins2 Taqman
found in the Supplemental Information.
(C) Ins1 and Ins2 gene expression assessed by Taqman real-time qPCR in arrayed
postnatal brain.
(D) Distribution of neurons expressing insulin protein in the hippocampus of 12-we
antibodies were validated with Ins1/:Ins2+/+ and Ins1+/+:Ins2/ mice (see the
(E) Close-up view of individual insulin neurons in the rostral cortex.
(F) Colocalization of insulin protein in cell bodies and axons (green), with b-gala
neurons (i), anterior olfactory nucleus neurons (ii), and cerebellar Purkinje neuron
(G) Confocal imaging of morphologically identified neurons showing punctate
endoplasmic reticulum (ER; green; iii) and in the somas of 7 day in vitro cultured ra
EGFP transfection was used to outline the boundaries andmorphological health of
neurons and staining was absent in neurons from Ins1/:Ins2/ mice (see the
See also Figures S1 and S2.
Cell Met al., 1993; Devaskar et al., 1993; Giddings et al., 1985; Havran-
kova et al., 1978; Lamotte et al., 2004;Wicksteed et al., 2010) (see
the Supplemental Information available online). Deep-
sequencing data from over 200 tissue libraries revealed broad
expression of Ins2, but not Ins1, in multiple regions of the devel-
opingandpostnatal brain (FigureS1A). Theobservation of central
nervous system (CNS) Ins2 prompted us to employ Taqman
quantitative PCR (qPCR) primers, validated in Ins2/ or Ins1/
islets (Figure S2A), to elucidate the expression pattern of insulin
in the brain. We observed brain expression of Ins2 messenger
RNA (mRNA), significantly above the background seen in Ins2/
brain tissue (Figures 1A and 1B). Ins1mRNAwas absent accord-
ing to these criteria. Using an array with complementary DNA
(cDNA) from multiple brain regions, we found Ins2 was broadly
expressed (most prominently in the hippocampus), while Ins1
was virtually absent (Figure 1C). Consistent with a local role for
neuronal insulin, quantitative analysis (Figure S2B) confirmed
that Ins2 expression in hippocampal neurons is much lower
than in pancreatic islets, which must deliver insulin to the entire
body. A similar RT-qPCR analysis of human brain cDNA array
confirmed INS expression in several regions, including hippo-
campus (Figure S1B). Chromatin immunoprecipitation with
antibodies to methylated histones, marking regions of active
transcription, followed by direct sequencing pointed to active
transcription around the Ins2 gene, but not the Ins1 gene, in
cerebral cortex and cerebellum (Figure S1C). Both genes had
activity marks in pancreatic islets (Figure S1C). Interestingly,
the active regions near the Ins2 locus inbrain appear tobedistinct
from those in islets. These observations are consistent withmany
reports that Ins2 promoters, but not Ins1 promoters, exhibit
robust activity in the brain (e.g., Wicksteed et al., 2010).
We studied the localization of insulin protein throughout the
brain using antibodies validated in Ins2/ or Ins1/ islets and
Ins1/:Ins2/ neurons (Figure S2C–S2E). Specific insulin im-
munoreactivity and C-peptide immunoreactivity were observed
in the hippocampus, anterior olfactory nucleus, cerebral cortex,
cerebellar Purkinje neurons, and other discrete nuclei (Figures
1D–1G). We also took advantage of the fact that the Ins2/
mice used in our studies had LacZ knocked into in their endog-
enous Ins2 locus (Figure S2E). We found that the same adult
neurons that were positive for bGal also stained robustly for
insulin protein in Ins1/:Ins2+/(bgal) mice (Figure 1F). To rulee hypothalamus, posterior brain, and anterior brain of 6-month-old wild-type
+/+ or Ins1+/+:Ins2/mice. These mice also provide ideal negative controls for
real-time qPCR primer/probe sets in Ins1 or Ins2 knockout mouse islets can be
cDNA frommultiple murine brain regions at multiple stages of developing and
ek-old mice (i). Hippocampal section stained without primary antibody (ii). The
Supplemental Information).
ctosidase knocked into the endogenous Ins2 locus (nucleus; red) in cortical
s (iii) from 12-week-old Ins1/:Ins2+/(bGal) mice.
and reticular C-peptide-2 immunoreactivity (red; ii) within calnexin-positive
t neonatal hippocampal neurons (approximately half of the cells were positive).
individual neurons (i). Identical results were observedwithmouse hippocampal
Supplemental Information). Error bars represent standard error of the mean.
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Insulin Gene Dosage Controls Mammalian Obesityout the possibility that insulin immunoreactivity arose from insulin
taken up into specific neurons via endocytosis, we cultured
hippocampal neurons in defined insulin-free media. Using an
antibody that recognizes mouse C-peptide 2, but not mouse
C-peptide 1 (Figure S2C), we identified endoplasmic reticulum
(ER) staining in cultured neurons (Figure 1G). The diffuse staining
pattern of insulin distribution, also observed with an antibody to
fully processed mature insulin, suggests a constitutive release
expected for a local trophic factor. Together, these data demon-
strate that Ins2 is produced in themammalian brain by a subset of
neurons, a feature conserved from lower animals (Rulifson et al.,
2002). Previous reports of insulin produced in the brain were
highly controversial because it was difficult to distinguish low
levels of insulin from background signals in the absence of ideal
negative controls (Ins2/ and/or Ins1/mice) and positive con-
trols [Ins1/:Ins2+/(bgal) mice]. The differential expression of two
murine insulin genesand the availability of Ins1and Ins2 knockout
mice presented a unique opportunity to specifically dissect the
role of circulating Ins1 derived from the pancreas.
Reduced Ins1 Prevents Diet-Induced b Cell Growth and
Fasting Hyperinsulinemia
To test the hypothesis that peripheral, pancreas-derived insulin
drives diet-induced obesity, we endeavored to selectively lower
circulating insulin by generating mice null for the brain-ex-
pressed Ins2 gene while modulating the gene dosage of
pancreas-specific Ins1 (Figure 2A). It was critical to first test
whether removal of one Ins1 allele in Ins2/ mice would result
in a proportional reduction in Ins1 mRNA and circulating insulin.
Indeed, Ins1+/:Ins2/ mice exhibited an 50% reduction in
islet Ins1 mRNA compared to Ins1+/+:Ins2/ mice (Figure 2B).
Analysis of insulin secretion and insulin content in islets in young
mice revealed some posttranscriptional compensation (Figures
2C and S4). However, by 1 year, insulin immunostaining, fasting
circulating insulin, and glucose-stimulated insulin secretion were
all markedly decreased in mice with reduced Ins1 gene dosage
(Figures 2D, 2I, and 3A).
Although the Ins1+/+:Ins2/ control mice used in these exper-
iments have been reported to be indistinguishable from wild-
type mice on a control diet (Duvillie´ et al., 1997; Leroux et al.,
2001), it was essential to determine whether they would respond
to a high-fat diet with a similar hyperinsulinemia and b cell mass
increase seen in other control strains (Okada et al., 2007). Rela-
tive to chow-fed controls, Ins1+/+:Ins2/mice fed a 58% fat diet
since weaning developed age-dependent, high-fat diet-induced
fasting hyperinsulinemia by 7 weeks of age (Figures 2I and S4A).Figure 2. Reduced Insulin Gene Dosage Prevents b Cell Expansion an
(A) Experimental design to test the role of circulating insulin on diet-induced obe
(B) qRT-PCR analysis of Ins1 mRNA in islets from 12-week-old mice (n = 3–5).
(C) Islet insulin content from 30 hand picked islets from 8-week-old mice (n = 3).
(D) Representative staining using anti-insulin (green) and anti-glucagon (red) an
evidence of islet autoimmunity.
(E) Ins1+/:Ins2/ mice failed to increase b cell mass in response to a high-fat d
(F) Cell death was assessed by measuring the number of TUNEL-positive b cells
(G and H) Proliferation was estimated by quantification of the percentage of PCNA
of PCNA immunoblot in islets isolated from 12-week-old mice (n = 4–6).
(I) Age-dependent high-fat diet-induced fasting hyperinsulinemia was prevented
*Significant difference between high-fat diet (HFD) mice (p < 0.05). **Significant dif
See also Figures S3 and S4.
Cell MPersistent hyperinsulinemia was dependent on the expression of
both Ins1 alleles.
The fasting hyperinsulinemia in high fat-fed Ins1+/+:Ins2/
mice was associated with an 2 fold increase in fractional
b cell area, compared with mice fed a control diet (Figure 2E).
However, in high fat-fed Ins1+/:Ins2/ mice, b cell area was
equivalent to control diet levels, pointing to a critical role for basal
circulating insulin in this process (Figure 2E). Analysis of pro-
grammed cell death and proliferation in b cells from Ins1+/:
Ins2/ mice suggested that circulating insulin had gene
dosage-dependent antiapoptotic and proproliferative autocrine
effects in the context of a high-fat diet (Figures 2F–2H). These
observations complement studies showing that mice lacking
insulin receptors on their b cells fail to increase b cell mass due
to defective proliferation and increased apoptosis (Okada
et al., 2007). Thus, long-term diet-induced fasting hyperinsuline-
mia was prevented in Ins1+/:Ins2/mice (Figure 2I), which was
associated with a lack of diet-induced b cell expansion (Fig-
ure 2E). In other words, we generated mice that were genetically
incapable of high-fat diet-induced fasting hyperinsulinemia. We
were unable to observe high-fat diet-induced hyperinsulinemia
or high-fat diet-induced obesity in female Ins2/ mice regard-
less of their Ins1 gene dosage (Figure S3). Male mice were
used for all subsequent studies designed to examine the effects
of diet on obesity.
Glucose Homeostasis in Mice with Reduced Insulin
Gene Dosage
Somewhat surprisingly, we observed only transient differences
in fasting glucose between Ins1+/:Ins2/ and Ins1+/+:Ins2/
mice, despite a modest reduction in glucose-stimulated insulin
release (Figures 3A, 3B, and S4B). Significant worsening of
glucose homeostasis in Ins1+/:Ins2/mice was only observed
in a small subset of high fat-fedmice (twomice) during the period
of rapid somatic growth around 11 weeks of age and was not
observed later in life or on the chow diet (Figure 3C). Insulin
sensitivity was generally similar between the genotypes and
diets (Figure 3D). Therefore, comparing Ins1+/+:Ins2/ mice
and Ins1+/:Ins2/mice enabled us to test the effects of genet-
ically reduced pancreatic insulin secretion on obesity, in the
absence of sustained hyperglycemia or insulin resistance.
Reduced Ins1 Gene Dosage Prevents Diet-Induced
Obesity
We directly tested the hypothesis that pancreatic insulin hyper-
secretion is required for diet-induced obesity by tracking bodyd Sustained Hyperinsulinemia on a High-Fat Diet
sity in the absence of Ins2.
tibodies in pancreas tissue sections from 12-month-old mice. We found no
iet (n = 3).
in pancreatic sections from 8-week-old mice (n = 3-5).
-positive b cells in pancreata from 8-week-old mice (n = 3) and by performance
in Ins1+/:Ins2/ mice (n = 6–16).
ference between control diet (CD)mice (p < 0.05). Error bars represent the SEM.
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Figure 3. Glucose Homeostasis and Insulin Sensitivity in Mice with Reduced Insulin Gene Dosage
(A) Insulin release in response to intraperitoneal injection of 18% glucose in 53-week-old mice.
(B) Four-hour fasted glucose levels measured weekly over the first year of life.
(C) Intraperitoneal glucose tolerance was impaired in young, but not old Ins1+/:Ins2/ mice. Insets show the area under the curve (AUC).
(D) Insulin tolerance was statistically similar between all groups at all ages studied. Insets show the area over the curve (AOC).
All data are represented as means of at least five male mice in each group at all time points. *Statistical significance (p < 0.05). Error bars represent the SEM. See
also Figures S3 and S4.
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Insulin Gene Dosage Controls Mammalian Obesityweight of Ins1+/+:Ins2/ mice and Ins1+/:Ins2/ mice, fed a
control diet or an obesigenic high-fat diet (Figure 4A). We ob-
served robust adult-onset obesity in male high fat-fed Ins1+/+:
Ins2/ control mice with all the expected hallmarks, including
increased fat-to-lean ratio measured by nuclear magnetic reso-
nance (NMR), increased fat pad weight, increased size of indi-
vidual adipocytes, and increased inflammation markers in white
adipose tissue (Figure 4). In striking contrast, Ins1+/:Ins2/728 Cell Metabolism 16, 723–737, December 5, 2012 ª2012 Elseviermice were completely protected from diet-induced adult-onset
weight gain for the duration of these 1-year-long experiments
(Figure 4A). The high-fat diet-induced increase in epididymal
fat pad weight was completely prevented (Figure 4B), resulting
in reduced circulating leptin (Figure 4C). Whole-body growth,
measured by tibia length, was independent of Ins1 gene dosage
(Figure 4D). Weights of other organs were not statistically
different between any of the groups (Figure 4E). Even at agesInc.
Cell Metabolism
Insulin Gene Dosage Controls Mammalian Obesityprior to the significant divergence of body weight between high
fat-fed groups, fasting insulin and body weight were positively
correlated between mice within genotypes (Figure S4). Together
with the results above, these data suggest that circulating Ins1 is
an adipocyte-specific and b cell-specific growth factor.
Next, we sought to determine the physiological mechanisms
accounting for the lack of high-fat diet-induced adiposity in the
nonhyperinsulinemic Ins1+/:Ins2/ mice (Figures 4F and 4G).
Using indirect calorimetry, we found increased energy expendi-
ture preceding the onset of differences in body weight (Fig-
ure 4H). The timing of this observation was important because
the normalization of energy expenditure between mice with dif-
ferent levels of adiposity is complicated (Himms-Hagen, 1997).
Notably, we did not observe significant differences in food
intake, physical activity, or respiratory quotient (Figures 4I–4L).
Collectively, these in vivo data suggest that high-fat diet-induced
hyperinsulinemia promotes adult adipocyte hypertrophy and
nutrient storage. The loss of one Ins1 allele was sufficient to
increase energy expenditure and prevent adiposity in the context
of a high-fat diet.
Ins1 Is a Negative Regulator of Uncoupling, Lipolytic,
and Inflammatory Genes in White Fat
We predicted changes in energy expenditure and fat cell growth
over this long time scale would be associated with stable alter-
ations in gene expression patterns and cellular reprogramming,
rather than only acute signaling events. Indeed, while hyperinsu-
linemic Ins1+/+:Ins2/ mice exhibited marked adipocyte hyper-
trophy, white adipose tissue from high fat-fed Ins1+/:Ins2/
mice appeared similar to that from mice fed a control diet
(Figure 5A). To determine the molecular mechanisms underlying
the protective effects of reduced circulating insulin, we designed
a Taqman real-time PCR miniarray of 45 key metabolic, inflam-
matory, and insulin target genes (see the Supplemental Informa-
tion for the rationale behind each gene choice). In white adipose
tissue, there were few differences between the two groups of
mice on the low-fat diet, although insulin receptor mRNA was
significantly decreased in Ins1+/ mice (Figure 5B). In keeping
with the lean phenotype and increased energy expenditure, we
observed a gene expression pattern associated with energy
expenditure and lipid mobilization, including increased expres-
sion of uncoupling proteins and Pnpla2 (adipose triglyceride
lipase), in white adipose tissue from high fat-fed Ins1+/:
Ins2/mice versus high fat-fed Ins1+/+:Ins2/mice (Figure 5B).
The increase in Ucp1 gene expression in white adipose tissue
isolated from high fat-fed Ins1+/:Ins2/mice suggested brown
adipose tissue-like features similar to what have been observed
in other lean models (Leonardsson et al., 2004). Ppargc1a
(Pgc1a) and Pparg, positive regulators of Ucp1 and energy
expenditure, were also upregulated at the mRNA level in white
adipose tissue from high fat-fed Ins1+/:Ins2/ mice. Further-
more, we observed downregulation of factors previously shown
to promote obesity and adipocyte differentiation in the white
adipose of high fat-fed Ins1+/:Ins2/mice, including the insulin
target Egr2 (Krox20) and Nrip1 (RIP140), a corepressor that
suppresses Ucp1 expression in white adipose tissue (Leonards-
son et al., 2004) (Figure 5B). Interestingly, none of the uncoupling
proteins were differentially expressed between brown adipose
tissue of high fat-fed Ins1+/:Ins2/ mice and high fat-fedCell MIns1+/+:Ins2/ mice (Figure S5A). We observed a tendency for
a gene expression profile promoting energy expenditure in skel-
etal muscle from high fat-fed Ins1+/:Ins2/ mice, although
these effects were not statistically significant with this sample
size (Figure S5B).
We selected a few differentially expressed genes with known
roles in insulin signaling and/or adipocyte differentiation for addi-
tional analysis at the protein level. Immunocytochemistry
showed what appeared to be enhanced Ucp1 protein in white
adipose tissue from high fat-fed Ins1+/:Ins2/mice compared
with high fat-fed Ins1+/+:Ins2/ littermates (Figure 5C). A signif-
icant increase in Ucp1 protein levels in high fat-fed Ins1+/:
Ins2/ mice was confirmed and quantified by immunoblot of
white adipose tissue (Figure 5D). We also observed elevated
protein levels of Pparg and Srebf1/SREBP-1c (Figure 5E), point-
ing to the upstream transcriptional control of this process by
insulin. Immunoblot also confirmed a significant decrease in
Egr2 protein in high fat-fed Ins1+/:Ins2/mice (Figure 5F), mir-
roring the effects on its mRNA and suggesting a possible ‘‘dedif-
ferentiation’’ of white adipocytes. These quantitative data clearly
demonstrate that the pancreas-specific Ins1 gene, and by exten-
sion the circulating insulin hormone, influences the expression of
a large number of key metabolic genes in white adipose tissue,
specifically in the context of a high-fat diet.
It is well established that obesity and insulin resistance are
associated with chronic low-grade inflammation of multiple
tissues, including white fat. However, the cause-and-effect rela-
tionships between these phenomena and hyperinsulinemia have
not been fully established. Our qRT-PCR analysis revealed a
broad reduction in inflammatory markers, including Tnfa and
Emr1 (F4/80; macrophages) in white adipose tissue from high
fat-fed Ins1+/:Ins2/ mice compared with high fat-fed Ins1+/+:
Ins2/ littermates. These data suggest that insulin regulates
adipose inflammation either directly (e.g., bymodulating immune
cells), or indirectly (e.g., via the effects on adipocyte size/stress).
Reduced Pancreatic Ins1 Protects Mice from Lipid
Spillover and Fatty Liver
Ins1+/:Ins2/ mice were protected from elevated circulating
free fatty acids when compared to their high fat-fed Ins1+/+:
Ins2/ littermate controls (Figure 6A). In accordance with the
lack of lipid spillover, livers of high fat-fed Ins1+/:Ins2/ mice
were protected fromhigh-fat diet-induced hepatic steatosis (Fig-
ure 6B) and associated stress pathway activation (Figure 6C).
The increase in liver triglyceride content in high fat-fed control
Ins1+/+:Ins2/mice was significantly reduced in Ins1+/:Ins2/
mice, while significant differences in cholesterol were not
observed (Figures 6D and 6E). qRT-PCR analysis of liver showed
that most of the differences were related to diet (reduced Ddit3,
Pparg, Ptpn1, Il6, Igfbp1, Egr1, and Egr2; increased Glut4,
Srebf1, Ppargc1a, and Pck1), rather than between genotypes
on the high-fat diet (Figure 6C). There were also notable differ-
ences in some inflammation markers in bulk liver tissue (Fig-
ure 6C). The reduction in the stress marker Atf3 (Figure 6C)
prompted us to evaluate markers of oxidative stress and lipid
peroxidation in this tissue, but the levels of protein carbonyl
and 4-hydroxynonenal (HNE) were not different between high
fat-fed Ins1+/:Ins2/mice and their high fat-fed Ins1+/+:Ins2/
littermates (Figure 6C). Our data support a paradigm wherebyetabolism 16, 723–737, December 5, 2012 ª2012 Elsevier Inc. 729
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Figure 4. Mice with Reduced Fasting Insulin Are Protected from High Fat-Induced Obesity as a Result of Increased Energy Expenditure
(A) Body weight tracked over 1 year, in multiple independent cohorts (assessed over several years; n = 5–11).
(B) Epididymal fat pad weight in 1-year-old mice (n = 5–11).
(C) Circulating leptin levels (n = 3).
(D and E) Tibial length and organ weight were measured at 1 year as indexes of somatic growth (n = 5–11).
(F and G) NMR spectroscopy (n = 3).
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Cell Metabolism
Insulin Gene Dosage Controls Mammalian Obesityhigh fat consumption leads to chronic basal insulin hypersecre-
tion (perhaps via direct insulinotropic effects of fatty acids),
which then increases adipocyte size and lipid accumulation in
adipose tissue. The spillover of free fatty acids subsequently
leads to steatosis and ER stress in the liver and other tissues,
which may eventually result in pathway- and/or tissue-specific
insulin resistance when combined with additional factors (Fig-
ure 7). The combination of these factors, initiated by hyperinsu-
linemia-induced obesity, could predispose individuals to type 2
diabetes.
DISCUSSION
Pancreatic Insulin Hypersecretion Drives Fat Storage
and Prevents Fat Burning in Adipocytes
A canon of diabetes and obesity research is that obesity-associ-
ated insulin resistance causes hyperinsulinemia because the
pancreatic b cells are hyperstimulated to release more insulin,
although the physiological mechanism for this hyperstimulation
remains unclear since it often occurs prior to hyperglycemia.
Our data demonstrate that prevention of high-fat diet-induced
hyperinsulinemia through partial ablation of the pancreas-
specific Ins1 gene protects mice from diet-induced obesity
and associated complications by upregulating genes that mobi-
lize lipids and increase mitochondrial uncoupling while downre-
gulating genes required for differentiation in white adipose
tissue. This would be expected to produce small amounts of
heat at the expense of maximal calorie storage in white fat.
Specifically, we propose a model for diet-induced obesity
whereby hyperinsulinemia normally negatively regulates white
adipose tissue Ucp1 expression, via a gene network involving
Pparg and Nrip1, to suppress energy expenditure (Figure 7).
This idea is consistent with the general anabolic role for insulin
and the observation that reducing circulating insulin with diazo-
xide promotes weight loss in obese mice via an increase in basal
metabolic rate (Alemzadeh et al., 2008). Our in vivo data place
the pancreas-specific Ins1 gene upstream of obesity, and estab-
lish the causality of circulating hyperinsulinemia in adult fat
growth in the absence of insulin resistance (Figure 7A). In our
study, increased basal insulin secretion occurred without sus-
tained hyperglycemia. Indeed, both insulin resistance and insulin
hypersecretion can occur in normoglycemic humans, preceding
obesity and insulin resistance (Genuth et al., 1971; Gray et al.,
2010; Ishikawa et al., 1998; Kitamura et al., 2003; Koopmans
et al., 1997; Le Stunff et al., 2001; Odeleye et al., 1997). It is
notable that early hyperinsulinemia was the strongest predictor
of type 2 diabetes in a 24 year study (Dankner et al., 2009). Insulin
resistance and obesity can also be uncoupled in human lipody-
strophies (Hegele, 2003) and in many mouse models (Bru¨ning
et al., 1998; Chen et al., 2010; El-Haschimi et al., 2003; Vijay-Ku-
mar et al., 2010; Wang et al., 2010). Further evidence for the
concept that hyperinsulinemia can be a primary factor in the
metabolic syndrome in humans can be found in the increased
risk of childhood weight gain observed in individuals with(H and I) Energy expenditure was measured by indirect calorimetry in high fat-fe
gain (n = 5).
(J–L) We did not note significant differences in activity, food intake, or respirator
*Statistical significance (p < 0.05). Error bars represent the SEM. See also Figure
Cell Melevated pancreatic insulin production caused by inheritance
of class I alleles of the INS gene (Le Stunff et al., 2001). Genetics
and epigenetics likely combine with environmental and dietary
factors that stimulate insulin hypersecretion early in life,
including in utero, to promote fat growth and eventually compli-
cations including type 2 diabetes. The therapeutic potential of
drugs that inhibit circulating insulin has previously been demon-
strated (Alemzadeh et al., 2008; Alemzadeh et al., 1998; Lustig
et al., 2006), but here we provide insight into the molecular
mechanism of these clinical observations. Our study provides
additional rationale for dietary and therapeutic efforts to partially
block insulin hypersecretion or peripheral insulin action
in specific tissues to combat obesity. However, insulin levels
must always be high enough to sustain glucose homeostasis.
Diet-Induced b Cell Expansion Is Regulated by Insulin
In Vivo
Elegant studies have suggested that insulin receptor signaling
modulates postnatal b cell mass expansion in response to
high-fat diet (Okada et al., 2007), but this concept has remained
controversial, in part due to the ability of insulin receptor manip-
ulations to influence IGF1 signaling and to cause compensatory
changes in other tissues. The lack of b cell mass ‘‘compensa-
tion’’ in Ins1+/:Ins2/ mice provides direct in vivo evidence
that insulin itself is critical for b cell growth and survival under
conditions of nutrient stress. Importantly, our results demon-
strate that b cell proliferation is induced in the absence of sus-
tained hyperglycemia in vivo. In the past, we have used in vitro
cultures of dispersed primary islet cells, a system where insulin
and glucose can be clamped independently of each other, to
demonstrate that insulin, but not glucose, stimulates b cell prolif-
eration (Beith et al., 2008; Johnson et al., 2006). We have also
shown that glucose-stimulated ERK activation is proportionally
reduced in islets with reduced insulin gene dosage or treated
with somatostatin to block insulin exocytosis (Alejandro et al.,
2010; Alejandro et al., 2011), strongly suggesting that glucose
modulates b cell fate mainly via local autocrine/paracrine insulin
signaling. Indeed, >80% of the effects of glucose on b cell gene
expression are lost in b cells with insulin receptor knockdown
(Ohsugi et al., 2005). Together, many lines of evidence from
multiple groups support the concept that insulin acts via insulin
receptors to mediate the compensatory increase in b cell mass
and basal insulin release in the context of high-fat diet. This
has implications for efforts to increase b cell mass in both type
1 and type 2 diabetes.
Tissue-Specific Roles for Ins1 and Ins2: Relevance to
Human INS
Insulin is the most studied hormone in biology, yet the present
study provides much needed integrated insight into its localiza-
tion and physiological functions in vivo. Clinically, insulin insuffi-
ciency resulting from a loss of greater than 80% of functional
b cell mass results in diabetes, promoting the prevailing mindset
that insulin’s roles are almost exclusively positive. Here we showd mice at 20 weeks of age (green star in A), just prior to differences in weight
y quotient (n = 3–5).
s S3 and S4.
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Figure 5. Molecular Mechanisms Leading to Protection from Diet-Induced Obesity in Ins1+/–:Ins2–/– Mice
(A) Hematoxylin and eosin-stained epididymal fat pad (n = 5–11).
(B) Taqman real-time qPCR quantification of 45 genes in epididymal white adipose tissue from 1-year-old mice. Results are sorted according to the magnitude of
the difference between high fat-fed Ins1+/:Ins2/mice and high fat-fed Ins1+/+:Ins2/ littermates (#p < 0.05). Geneswith a large negative relative expression are
colored red; genes with increased expression are green. $Significant difference between diets in the Ins1+/:Ins2/mice. &Significant difference between diets in
the Ins1+/+:Ins2/ mice. *Significant difference between genotypes on the control diet. Data are from 1-year-old mice (n = 5–11), unless otherwise specified.
(C) Ucp1 immunocytochemistry in white adipose tissue from 1-year-oldmice. The inset shows results from the identical staining protocol on brown adipose tissue
sections.
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Insulin Gene Dosage Controls Mammalian Obesitythat insulin hypersecretion from b cells can be maladaptive.
Similarly, elegant studies in flies and worms have demonstrated
that deleting insulin genes, or blocking elements of the insulin
signaling pathway, dramatically increases life span and prevents
diseases associated with adiposity (Broughton et al., 2008; Li
et al., 2003). These model systems also clearly indicate that indi-
vidual insulin-like peptide genes have distinct functions despite
signaling through a single receptor (Broughton et al., 2008; Li
et al., 2003). In rodents, the Ins1 and Ins2 genes are under
partially distinct regulation (Alejandro et al., 2011; Hay and Doch-
erty, 2006). Previously, it has also been shown that the mouse
Ins1 and Ins2 genes have opposing roles on type 1 diabetes inci-
dence in theNODmouse due to the induction of thymic tolerance
by Ins2 (Fan et al., 2009; Moriyama et al., 2003), but the possi-
bility that they have distinct roles in obesity had not been
examined.
In the present study, we elucidated the tissue-specific
patterns of Ins1 and Ins2 expression. Usingmultiple approaches,
we found that Ins2 is present in CNS neurons, at both the mRNA
and protein levels. Uniquely, we present both negative and posi-
tive controls, arguing against qPCR or staining artifacts. We also
find distinct active chromatin marks on the Ins2 gene in the CNS
and provide RNA sequencing data. Given the conservation
between the rodent Ins2 gene and the human INS gene, we
were not surprised to find additional evidence for insulin produc-
tion in the human brain. In both species, we find robust insulin
expression in the hippocampus, pointing to potential roles in
learning and memory. It is interesting to note the recent interest
in clinical trials using nasal insulin to replace this putative central
neurotrophic factor for the treatment of Alzheimer’s disease. A
complete understanding of the role of Ins2 produced in the
CNS will require brain-specific Ins2 knockout mice.
We predict that insulin produced locally in specific brain
regions will have potent effects on food intake (Hallschmid
et al., 2012). Based on recent studies, we expect that some
insulin circuits will promote food intake, while others will
suppress it, and we predict that distinct populations of insulin
neurons will be differentially susceptible to insulin resistance
(Ko¨nner and Bru¨ning, 2012; Rother et al., 2012). It should be
noted that our data do not address what may be an important
role of peripheral insulin acting on the brain in the lean phenotype
of our mice. Within and outside the brain, we predict that the
source of the insulin is critical for its effect on obesity.
Conclusions
We generated mice that were genetically incapable of age-
dependent, diet-induced fasting hyperinsulinemia, and thereby
demonstrated that circulating insulin plays a causal role in
obesity in this model (Figure 7). We identify circulating insulin
as a critical regulator of Ucp1 expression in white adipose tissue
and whole-body energy expenditure. We find that increased fat
burning in white adipose tissue is associated with reduced lipid(D) Immunoblot for Ucp1 in white adipose tissue. Lane 1 is brown adipose tissue
and Ponceau staining (pink). Quantification bars are the normalized ratio to b-ac
(E) Immunoblots of Pparg and Srebf1.
(F) Immunoblot analysis of Egr2.
*p < 0.05 versus high fat-fed Ins1+/+:Ins2/ littermates (n = 4–5). Error bars repr
Cell Maccumulation in liver. Our data provide strong rationale to inves-
tigate approaches to limit peripheral hyperinsulinemia for the
prevention and treatment of obesity in mammals.
EXPERIMENTAL PROCEDURES
Experimental Animals and Glucose Homeostasis
Animal protocols were approved by the University of British Columbia Animal
Care Committee in accordance with national and international guidelines.
Ins1/ and Ins2/ mice were generated by the group of J. Jami (INSERM,
France), and their baseline phenotype described elsewhere (Duvillie´ et al.,
1997). C57Bl6/J mice (Jackson Laboratory, Bar Harbor, ME) were employed
for some studies, as indicated. Male mice were used unless otherwise noted.
Groups of mice were randomly divided into two diet groups at weaning
(3 weeks), and fed a control diet (25% fat) or a high-fat diet (58% fat). Additional
details of the diet composition can be found in the Supplemental Information.
Body weight, fasting glucose, glucose tolerance, and insulin tolerance were
examined after 4 hr fasts according to standard methods we have previously
described in more detail (Alejandro et al., 2011). The insulin-positive area was
used as an index of b cell mass, as described previously (Alejandro et al.,
2011). The cell death was assayed with the Roche TUNEL kit (Alejandro
et al., 2011). Serum insulin levels were measured with an ultrasensitive ELISA
kit (80-INSMSU-E01; ALPCO Diagnostics, Salem, NH). Leptin levels were
measured with mouse leptin ELISA kit (number 90030; CrystalChem, Downers
Grove, IL).
In Vivo Metabolic Analysis
PhenoMaster metabolic cages (TSE Systems, Chesterfield, MO) were used
for indirect calorimetry, activity, body weight, and food intake studies in
accordance with the manufacturer’s instructions. After 52 weeks of age,
mice were scanned for whole-body fat to lean mass ratio via NMR Spec-
troscopy at the 7T MRI Research Center (University of British Columbia,
Vancouver, Canada). Circulating fatty acids were measured with the Wako
NEFA kit.
Gene Expression and Protein Analysis
Mouse and human cDNA arrays, from tissue collected under IRB protocols,
were purchased from Origene (Rockville, MD). Gene expression analysis
was conducted with custom arrays of Taqman Real-Time PCR Assays (Life
Technologies, Burlington, Canada). Immunoblotting and staining were con-
ducted according to standard protocols (Alejandro et al., 2011). Brains were
frozen prior to cryosectioning, while all other tissues were fixed in 4% parafor-
maldehyde. Paraffin block sectioning and hemotoxyn and eosin staining were
conducted by the Histology Core at the Child and Family Research Institute
(Vancouver, Canada). The following antibodies were used in immunofluores-
cence studies of neurons and b cells: polyclonal rabbit anti-C-peptide-2 (Milli-
pore), monoclonal mouse anti-mature insulin (Biodesign), and polyclonal
guinea pig anti-(pan)insulin (Sigma). Uncoupling protein 1 protein levels were
quantified with antibodies from Santa Cruz (catalog number sc-6829), with
brown adipose tissue used as a positive control. Imageswere taken with either
an Olympus FV1000 confocal microscope or a Zeiss 200mmicroscope equip-
ped with deconvolution software (Slidebook, Intelligent Imaging Innovartions,
Denver, CO).
Statistical Analysis
Studies were repeated at least three times. All results are expressed asmean ±
SEM (indicated by error bars). Statistical analyses were performedwith Graph-
pad Prism 5 or Microsoft Excel. A student’s t test or AVOVA (Tukey’s) were
used as appropriate. A p value < 0.05 was considered significant.(positive control). Equal protein loading was confirmed by b-actin immunoblot
tin (n = 4–5).
esent the SEM. See also Figure S5.
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Figure 6. Mice with Reduced Ins1 Are Protected from Lipid Spill Over, Fatty Liver and ER Stress
(A) Circulating free fatty acids levels.
(B) Low and high magnification of hematoxylin and eosin-stained liver.
(C) Taqman real-time qPCR quantification of 49 genes in liver (n = 3–7 individual mice). Results are sorted as in Figure 3. #p < 0.05 (t test) between high fat-fed
Ins1+/:Ins2/ mice versus high fat-fed Ins1+/+:Ins2/ mice. $Significant difference between diets within the Ins1+/:Ins2/ mice. &Differences between
Ins1+/:Ins2/ mice versus Ins1+/+:Ins2/ mice on the control diet.
(D and E) Liver triglyceride and cholesterol measurements (n = 3–5).
(F and G) Markers of oxidative stress, protein carbonyl and 4-hydroxynonenal NHE, were measured in livers (n = 4–6). All data are from 1-year-old mice.
Error bars represent the SEM. See also Figure S5.
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Figure 7. Revisiting the Current Model of
Obesity and Type 2 Diabetes
(A) The most widely accepted model of the path-
ogenesis of obesity and type 2 diabetes posits that
a high-fat diet leads to obesity and insulin
resistance (there is debate about the relative order
and causality of these). In this widely held view,
insulin resistance then leads to hyperinsulinemia,
which is followed by b cell exhaustion, and then
type 2 diabetes. The accepted model is incom-
patible with our results that put the insulin hyper-
secretion genetically upstream of obesity.
(B) Our data support a model whereby insulin
levels must be kept low to maintain energy ex-
penditure in white adipose tissue via the expres-
sion of Ucp1. Our data do not address the order
of subsequent events after obesity (outside the
yellow box), such as insulin resistance and/or
type 2 diabetes, since they were not observed in
our studies. In other words, the effects of insulin
gene dosage on obesity are independent of sus-
tained changes in glucose homeostasis or insulin
resistance.
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